Elevated Lipoprotein(a) or Lp(a) is increasingly recognized as a significant, independent risk enhancer for cardiovascular disease (CVD). This course explores the evolving landscape of Lp(a) in clinical practice, emphasizing the importance of Lp(a) testing in comprehensive cardiovascular risk assessment. The safety and efficacy of current and emerging lipid-lowering therapies, with a focus on novel agents targeting Lp(a) reduction will be examined.
Claim CE and MOC credits: https://bit.ly/4r1xjU6
